Aseptic Formulations Facility for Global Supply

Due to the nature of the difference in the Innovative 505(b)(2) products and Generic activities Mapi is considering forming a fully integrated separate manufacturing company focused on generic opportunities of versions of long-acting depots such as the following that were developed by Mapi: • Paliperidone (Invega Sustenna®) • Paliperidone (Invega Trinza®) • Aripiprazole (Ability Maintena®) • Naltrexone (Vivitrol®) • Aripiprazole (Aristada®) • Generic Copaxone 20mg/40mg in PFS based on Mapi API